News | September 22, 2008

Oropharyngeal Cancer Patients Show Less Salivary Gland Toxicity

September 23, 2008 – A multicenter trial testing intensity-modulated radiation therapy (IMRT) for patients with early stage oropharyngeal cancer showed a reduction in long-term salivary toxicity while achieving good tumor control according to new research from the Radiation Therapy Oncology Group (RTOG) presented at ASTRO 2008.

RTOG launched its phase I/II trial, RTOG 0022, to determine whether standardized dose and target definitions for IMRT could be accomplished in a multicenter setting. A total of 69 patients were entered on study from February 2001 through January 2005 from 14 academic and community institutions in the U.S. and Canada. A two-year local-regional control rate of 91 percent and a 49 percent rate of acute salivary gland toxicity (Grade 2) was reported by investigators compared with 80 and 84 percent in the same patient population from the RTOG database. The rate of salivary gland toxicity dropped to 23 percent at one year and 13 percent at two years. Evaluable patients who, at central review of their treatment plan, where found to have a major variation in their radiotherapy treatment plan had a significantly higher rate of local-regional failure than patients who were treated according to protocol (50 vs. 6 percent).

All institutions participating in the trial were pre-approved for IMRT by the Image-guided Therapy QA Center (ITC) at Washington University in St. Louis.

For more information: www.astro.org

Source: American Society For Therapeutic Radiology and Oncology

Related Content

more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Surgery and High-Dose SBRT Radiation Can Be Combined to Treat Kidney Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | July 05, 2017
A new study from Roswell Park Cancer Institute reporting the findings of the first clinical trial to evaluate the...
ASTRO Issues Guideline for Stereotactic Radiation Use in Early-Stage Lung Cancer
Feature | Lung Cancer | June 23, 2017
The American Society for Radiation Oncology (ASTRO) recently issued a new clinical guideline for the use of...
stereotactic body radiation therapy (SBRT)
News | Stereotactic Body Radiation Therapy (SBRT) | June 12, 2017
The American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of stereotactic body...
Stereotactic Radiation Highly Effective for Kidney Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | May 03, 2017
Kidney cancer patients may soon have an alternative to traditional treatments, according to new research at UT...
SBRT, stereotactic body radiation therapy, early-stage lung cancer, patients 80 and older, 2017 Multidisciplinary Thoracic Cancers Symposium, study
News | Stereotactic Body Radiation Therapy (SBRT) | March 20, 2017
Patients in their 80s and 90s who have early-stage lung cancer but cannot undergo an operation can be treated safely...
prostate cancer, partial gland, SBRT, clinical trial, UH Hospitals
News | Stereotactic Body Radiation Therapy (SBRT) | April 28, 2016
Physicians at University Hospitals Seidman Cancer Center (Cleveland) have started a clinical trial using a new form of...
prostate cancer, stereotactic body radiation therapy, SBRT, cure rate, UT Southwestern Study
News | Prostate Cancer | April 19, 2016
A five-year study shows that stereotactic body radiation therapy (SBRT) offers a higher cure rate for prostate cancer...
Overlay Init